Additionally, the 36-month beta value for PCRX is 0.51. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 1 rating it as “overweight,” 3 rating it as “hold,” and 0 rating it as “sell.”
The public float for PCRX is 44.31M and currently, short sellers hold a 13.17% ratio of that float. The average trading volume of PCRX on June 19, 2025 was 883.79K shares.
PCRX) stock’s latest price update
The stock price of Pacira BioSciences Inc (NASDAQ: PCRX) has plunged by -0.98 when compared to previous closing price of 24.39, but the company has seen a -0.78% decline in its stock price over the last five trading sessions. zacks.com reported 2025-06-18 that Investors need to pay close attention to PCRX stock based on the movements in the options market lately.
PCRX’s Market Performance
PCRX’s stock has fallen by -0.78% in the past week, with a monthly drop of -7.65% and a quarterly drop of -0.54%. The volatility ratio for the week is 0.72% while the volatility levels for the last 30 days are 1.41% for Pacira BioSciences Inc The simple moving average for the past 20 days is -5.23% for PCRX’s stock, with a 13.59% simple moving average for the past 200 days.
Analysts’ Opinion of PCRX
Many brokerage firms have already submitted their reports for PCRX stocks, with Truist repeating the rating for PCRX by listing it as a “Hold.” The predicted price for PCRX in the upcoming period, according to Truist is $25 based on the research report published on January 30, 2025 of the current year 2025.
Truist, on the other hand, stated in their research note that they expect to see PCRX reach a price target of $8, previously predicting the price at $30. The rating they have provided for PCRX stocks is “Sell” according to the report published on August 13th, 2024.
RBC Capital Mkts gave a rating of “Sector Perform” to PCRX, setting the target price at $14 in the report published on August 12th of the previous year.
PCRX Trading at -5.29% from the 50-Day Moving Average
After a stumble in the market that brought PCRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -18.44% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PCRX starting from RIKER LAUREN, who sale 5,578 shares at the price of $26.21 back on Jun 04 ’25. After this action, RIKER LAUREN now owns 59,564 shares of Pacira BioSciences Inc, valued at $146,208 using the latest closing price.
WILLIAMS KRISTEN, the Chief Administrative Officer of Pacira BioSciences Inc, sale 14,376 shares at $26.24 during a trade that took place back on Jun 04 ’25, which means that WILLIAMS KRISTEN is holding 161,574 shares at $377,226 based on the most recent closing price.
Stock Fundamentals for PCRX
Current profitability levels for the company are sitting at:
- -0.12 for the present operating margin
- 0.74 for the gross margin
The net margin for Pacira BioSciences Inc stands at -0.15. The total capital return value is set at -0.06. Equity return is now at value -12.27, with -6.54 for asset returns.
Based on Pacira BioSciences Inc (PCRX), the company’s capital structure generated 0.44 points at debt to capital in total, while cash flow to debt ratio is standing at 0.28. The debt to equity ratio resting at 0.8. The interest coverage ratio of the stock is -5.32.
Currently, EBITDA for the company is 32.25 million with net debt to EBITDA at 17.52. When we switch over and look at the enterprise to sales, we see a ratio of 2.09. The receivables turnover for the company is 6.71for trailing twelve months and the total asset turnover is 0.44. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.41.
Conclusion
In conclusion, Pacira BioSciences Inc (PCRX) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
